D., Zdravkovic, M., & Moerch, U
"New treatment options expand choice and help more people find care that fits their lives, their goals and where they are in their journey whether they're just starting to explore treatment or looking for a different long-term approach." Lilly has submitted orforglipron for weight management and/or type 2 diabetes in more than 40 countries and plans to launch in each country shortly after approval.
Support: Ongoing guidance ensures safe and effective results
These include cases where metformin is ineffective, contraindicated, or when a clients A1C remains above target levels despite three months of treatment if they also have conditions like atherosclerosis, heart failure, or chronic kidney disease (6)(16)
Tirzepatide is a once-weekly subcutaneous peptide that activates two incretin receptors simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor
Regular Monitoring: Follow-up appointments and lab work ensure were achieving desired outcomes and can adjust protocols as needed